Bigbear Pharmaceutical·Medication Guide

• Important Precautions for Ritlecitinib Use

  As a selective Janus kinase (JAK) inhibitor, ritlecitinib modulates immune responses mainly by inhibiting the activities of JAK1 and JAK3, providing a···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 163

• Dosage and Administration Guidelines for Ritlecitinib

  Ritlecitinib is an oral small‑molecule drug belonging to the class of dual JAK3/TEC kinase inhibitors, mainly used for the treatment of autoimmune dis···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 172

• What is alpelisib

  Alpelisib (Piqray brand) is used to treat types of breast cancer in men and postmenopausal women, and Vijoice brand of alpelisib is used to treat a co···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 165

• What happens if I miss a dose

  Take the medicine (with food) as soon as you can, but skip the missed dose if you are more than 9 hours late for the dose. Do not use two doses at one···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 163

• What other drugs will affect alpelisib

  Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may incre···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 171

• What should I avoid while taking alpelisib

  Follow your doctor's instructions about any restrictions on food, beverages, or activity.【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 166

• Alpelisib: Number of Boxes per Treatment Cycle, Cost and Contraindications

  Alpelisib is a targeted therapy directed against PIK3CA mutations, developed by Novartis Pharmaceuticals of Switzerland. This article provides a detai···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 164

• Purchase Channels and Dosing Guidelines for Alpelisib

  Alpelisib is a targeted therapy for specific types of breast cancer. The drug is not yet approved in mainland China and is not covered by medical insu···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 141

• First PIK3CA-Mutated HR+/HER2- Breast Cancer Therapy Piqray (Alpelisib) Significantly Prolongs Overa

  Novartis announced the final overall survival (OS) analysis results from the phase III SOLAR‑1 study of Piqray (alpelisib), a novel breast cancer ther···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 163

• Breast Cancer New Drug Piqray for PIK3CA-Mutated HR+/HER2- Breast Cancer: Significantly Extends Surv

  Novartis recently announced the final overall survival (OS) analysis results of the phase III SOLAR-1 study of the new breast cancer drug Piqray (alpe···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 154

• Novartis PI3K Inhibitor Piqray Approved in the EU: First Therapy for PIK3CA-Mutated HR+/HER2- Breast

  EU Approval Details of PiqrayNovartis recently announced that the European Commission (EC) has approved Piqray (alpelisib) in combination with fulvest···【Read More】

  Update: 2026-03-02Source: Haiou HealthViews: 150

• Detailed Prescribing Information for Cabozantinib: Indications, Dosage and Administration, Side Effe

  Cabozantinib is a broad-spectrum, multi-target anti-tumor drug developed by Exelixis Biopharmaceuticals, Inc. While most anti-tumor drugs target 1-3 t···【Read More】

  Update: 2026-02-28Source: Haiou HealthViews: 169

• The FDA has approved cabozantinib (Cabometyx) for patients with previously treated advanced neuroend

  On March 26, 2025, Exelixis announced that the U.S. Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx) for the treatment of two ···【Read More】

  Update: 2026-02-28Source: Haiou HealthViews: 146

• Common Dosage of Cabozantinib

  Cabozantinib is a small-molecule, multi-target tyrosine kinase inhibitor developed by Exelixis in the United States. In November 2012, the FDA first a···【Read More】

  Update: 2026-02-28Source: Haiou HealthViews: 178

• Cabozantinib Side Effects Requiring Immediate Medical Attention

  Cabozantinib is a broad-spectrum anticancer drug targeting multiple targets, inhibiting at least nine targets including MET, VEGFR1/2/3, ROS1, RET, AX···【Read More】

  Update: 2026-02-28Source: Haiou HealthViews: 158